BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31731087)

  • 1. Neurotoxicity of antibodies in cancer therapy: A review.
    Horta E; Bongiorno C; Ezzeddine M; Neil EC
    Clin Neurol Neurosurg; 2020 Jan; 188():105566. PubMed ID: 31731087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
    Xu M; Nie Y; Yang Y; Lu YT; Su Q
    Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study.
    Rizzo A; Santoni M; Mollica V; Logullo F; Rosellini M; Marchetti A; Faloppi L; Battelli N; Massari F
    Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1455-1466. PubMed ID: 35029519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible metronidazole-induced neurotoxicity after 10 weeks of therapy.
    AlDhaleei W; AlMarzooqi A; Gaber N
    BMJ Case Rep; 2018 Apr; 2018():. PubMed ID: 29678819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drugs and the Nervous System.
    Santomasso BD
    Continuum (Minneap Minn); 2020 Jun; 26(3):732-764. PubMed ID: 32487905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
    Raibagkar P
    Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
    [No Abstract]   [Full Text] [Related]  

  • 7. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
    Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA
    Cancer Treat Rev; 2016 Nov; 50():118-128. PubMed ID: 27664395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.
    McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB;
    Support Care Cancer; 2017 Nov; 25(11):3485-3493. PubMed ID: 28589310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
    Pan PC; Haggiagi A
    Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
    Press MF; Lenz HJ
    Drugs; 2007; 67(14):2045-75. PubMed ID: 17883287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers.
    Banach M; Juranek JK; Zygulska AL
    Brain Behav; 2017 Jan; 7(1):e00558. PubMed ID: 28127506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors.
    Mohrmann C; Armer J; Hayashi RJ
    J Pediatr Oncol Nurs; 2017; 34(2):106-114. PubMed ID: 27251891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
    Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W
    Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
    Vilariño N; Bruna J; Kalofonou F; Anastopoulou GG; Argyriou AA
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity induced by antineoplastic proteasome inhibitors.
    Alé A; Bruna J; Navarro X; Udina E
    Neurotoxicology; 2014 Jul; 43():28-35. PubMed ID: 24525285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials.
    Li J; Yan H
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):571-583. PubMed ID: 30006755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotoxicity of cancer chemotherapy.
    Dropcho EJ
    Semin Neurol; 2004 Dec; 24(4):419-26. PubMed ID: 15637653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
    Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
    Front Immunol; 2020; 11():895. PubMed ID: 32528470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.